Mode
Text Size
Log in / Sign up
N/A Completed N=209 Randomized Single-blind Treatment

Evaluation of an Intervention for Young Adults With Diabetes: Resilient, Empowered, Active Living-Telehealth (REAL-T)

Diabetes Mellitus, Type 1
Source: ClinicalTrials.gov NCT04023487 ↗
Enrolled (actual)
209
Serious AEs
29.7%
Results posted
Aug 2024
Primary outcomePrimary: Change From Baseline to 6-months in Glycemic Control, Using Glycated Hemoglobin (HbA1C) — -0.44; -0.31 percentage of glycosylated hemoglobin

Summary

This study will evaluate (1) the efficacy of REAL-T, a lifestyle-based telehealth intervention, in improving glycemic control (HbA1c) and psychosocial outcomes, (2) which effects are retained over a 6-month follow-up period, and (3) the mediating mechanisms responsible for the intervention's effects. Half of participants will receive REAL-T, while the other half will receive their usual care.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline to 6-months in Glycemic Control, Using Glycated Hemoglobin (HbA1C)
-0.44; -0.31
SECONDARY
Change From Baseline to 6-months Post-test in Diabetes-related Quality of Life, Using the "Audit of Diabetes-Dependent Quality of Life-15" (ADD-QoL-15)
0.39; -0.15
SECONDARY
Change From Baseline to 6-months Post-test in Diabetes-related Emotional Distress, Using the "Diabetes Distress Scale" (DDS)
-0.48; -0.25
SECONDARY
Change in Functional Health and Well-being, Using the "SF-12v2® Health Survey"
SECONDARY
Change in Global Diabetes Self-management, Using the "Diabetes Self-Management Questionnaire-Revised" (DSMQ-R).
SECONDARY
Change in Medication Adherence, Using the "3-item Adherence Self-report Scale" Questionnaire
SECONDARY
Change in Self-efficacy for Performing Diabetes Self-management, Using the "Diabetes Empowerment Scale - Short Form" (DES-SF)
SECONDARY
Change in Autonomy of Taking Insulin and/or Checking Blood Sugar, Using the "Treatment Self-Regulation Questionnaire" (TSRQ)
SECONDARY
Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time-in-Range
4.44; 1.02
SECONDARY
Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time in Hyperglycemia
-4.48; -1.61
SECONDARY
Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time in Hypoglycemia
0.04; 0.59
SECONDARY
Change in Cost to Patients
SECONDARY
Change in Cost to Payor

Eligibility Criteria

Inclusion Criteria

  • T1D for ≥12 months
  • A1c ≥7.5% at time of study enrollment
  • Age 18-30 yrs. at time of study enrollment
  • English or Spanish speaking
  • Resides in a state where OT clinicians are licensed, in an area where the participant has access to a local healthcare provider in the event of emergency and can complete data collection in person (when permitted) or via mailings (when required during period of social distance or due to distance from study site)
  • Participant has access to a laptop or desktop computer, either their own or loaned by the study (if geographically feasible and permitted given COVID-19 social distancing distractions)
  • Willing to participate in 6-month intervention

Exclusion Criteria

  • Currently pregnant or planning to become pregnant within the next 12 months
  • Previously received REAL intervention
  • Cognitive impairment or severe disability limiting life expectancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04023487). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search